Physician Evaluations

Adding an SGLT-2 inhibitor had an incremental cost-effectiveness ______ of $73,000/QALY

Quadruple therapy was assessed as only “borderline cost effective” vs adding an SGLT-2 inhibitor alone to the previous standard of ______.

Increasing physician age and longer time since graduation predict overall ______ performance.

Older physicians tend to rely more on experiences rather than analytical cognitive ______, and their fluid intelligence decreases with age.

______ is a GLP-1 receptor agonist and a GLP/GIP receptor agonist. It has dual actions on appetite hormones and produces significant weight loss.

These medications have different contraindications and side effects, and they require a dose escalation to minimize side effects. It's important to consider the individual patient's characteristics and health conditions when prescribing these ______.

Lifestyle changes, such as improving diet quality and increasing physical activity, should also be part of the ______ management approach.

• Weight gain and weight loss are influenced by more than 200 contributing genes, environmental factors (including diet and weight loss efforts), and medications as they modify appetite hormones and ______.

• These medications work through appetite regulation, with semaglutide showing the most substantial average weight loss (15-17%). Safety and tolerability should be considered, and each medication has specific contraindications and ______.

• Anti-obesity medications are indicated for patients with a BMI of 30 or higher or a BMI of 27 with at least one obesity-related ______. They should not be used for cosmetic weight loss.

• The primary care setting is ideal for addressing weight management since it contributes to better chronic disease ______.

They review the clinical challenges around achieving weight loss in your patients. They review the drivers of weight ______ the challenges with weight loss, the physiology behind the disease drivers of ectopic fat accumulation, and provide clear, practical guidance around selection and use of the newer anti-obesity drugs.

Obesity is defined as excess abnormal body fat that ______ health. BMI is a screening tool.

Weight gain and weight loss are influenced by more than 200 contributing genes, environmental factors (including diet and weight loss efforts), and medications as they modify appetite hormones and ______.

Lifestyle changes, such as improving diet quality and increasing physical activity, should also be part of the ______ management approach.